BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast

Reuters

Oct 16

BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast

The hosts are Reuters Breakingviews columnists. The opinions expressed are their own.

By Aimee Donnellan and Jonathan Guilford

DUBLIN/NEW YORK, Oct 16 (Reuters Breakingviews) - Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

Listen to the podcast

In many cases, the market charges nearly triple what others do, a discrepancy that has put President Trump on the warpath. In this Viewsroom podcast, Breakingviews columnists discuss how Americans subsidize novel treatments and how tricky it will be to spread the burden.

Follow Aimee Donnellan on LinkedIn.

Follow Jonathan Guilford on X and LinkedIn.

FURTHER READING

Big Pharma prevails in art of the drug deal

Big Pharma’s tariff win leaves lingering aches

Obesity kings’ buffet is slimmer than it looks

Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.

(Editing by Sheryl Peña and Gregory Garner; Production by Aditya Srivastav)

((katrina.hamlin@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575277795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575277795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575277795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 12:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575277795","market":"nz","top_or_hot":-1,"title":"BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast</title></head><body><p>The hosts are Reuters Breakingviews columnists. The opinions expressed are their own.</p><p>By Aimee  Donnellan and Jonathan  Guilford</p><p>\n<span>DUBLIN/NEW YORK, Oct 16 (Reuters Breakingviews)</span><span> - </span>Follow on Apple or <a href=\"https://laohu8.com/S/SPOT\">Spotify</a>. Listen on the Reuters app. Read the episode transcript.</p><p>\nListen to the podcast\n</p><p>In many cases, the market charges nearly triple what others do, a discrepancy that has put President Trump on the warpath. In this Viewsroom podcast, Breakingviews columnists discuss how Americans subsidize novel treatments and how tricky it will be to spread the burden.</p><p>Follow Aimee Donnellan on LinkedIn.</p><p>Follow Jonathan Guilford on X and LinkedIn.</p><p>FURTHER READING</p><p>\n<span>Big Pharma prevails in art of the drug deal</span>\n</p><p>\n<span>Big Pharma’s tariff win leaves lingering aches</span>\n</p><p>\n<span>Obesity kings’ buffet is slimmer than it looks</span>\n</p><p>Visit the <a href=\"https://laohu8.com/S/TMSOF\">Thomson Reuters</a> Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.   </p><p>(Editing by Sheryl Peña and Gregory Garner; Production by Aditya Srivastav)</p><p>((katrina.hamlin@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 12:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast</title></head><body><p>The hosts are Reuters Breakingviews columnists. The opinions expressed are their own.</p><p>By Aimee  Donnellan and Jonathan  Guilford</p><p>\n<span>DUBLIN/NEW YORK, Oct 16 (Reuters Breakingviews)</span><span> - </span>Follow on Apple or <a href=\"https://laohu8.com/S/SPOT\">Spotify</a>. Listen on the Reuters app. Read the episode transcript.</p><p>\nListen to the podcast\n</p><p>In many cases, the market charges nearly triple what others do, a discrepancy that has put President Trump on the warpath. In this Viewsroom podcast, Breakingviews columnists discuss how Americans subsidize novel treatments and how tricky it will be to spread the burden.</p><p>Follow Aimee Donnellan on LinkedIn.</p><p>Follow Jonathan Guilford on X and LinkedIn.</p><p>FURTHER READING</p><p>\n<span>Big Pharma prevails in art of the drug deal</span>\n</p><p>\n<span>Big Pharma’s tariff win leaves lingering aches</span>\n</p><p>\n<span>Obesity kings’ buffet is slimmer than it looks</span>\n</p><p>Visit the <a href=\"https://laohu8.com/S/TMSOF\">Thomson Reuters</a> Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.   </p><p>(Editing by Sheryl Peña and Gregory Garner; Production by Aditya Srivastav)</p><p>((katrina.hamlin@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0466842654.USD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VW13C:1","article_id":"2575277795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575277795","pubTimestamp":1760590515,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcastThe hosts are Reuters Breakingviews columnists. The opinions expressed are their own.By Aimee  Donnellan and Jonathan  Guilford. DUBLIN/NEW YORK, Oct 16  - Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.In many cases, the market charges nearly triple what others do, a discrepancy that has put President Trump on the warpath. In this Viewsroom podcast, Breakingviews columnists discuss how Americans subsidize novel treatments and how tricky it will be to spread the burden.Follow Aimee Donnellan on LinkedIn.Follow Jonathan Guilford on X and LinkedIn.FURTHER READING","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","PFE":"辉瑞","LLY":"礼来","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU1880407215.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) INC","03165":"华夏欧优股对冲","SG9999001176.USD":"United Global Healthcare Acc USD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BKPKM643.USD":"NEUBERGER BERMAN EUROPEAN SUSTAINABLE EQUITY \"A\" (USDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0345777147.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","AZN.UK":"阿斯利康制药","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC"},"translate_title":"突发新闻-削减美国药品价格是有代价的：播客","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AZN.UK":0.9,"LLY":0.9,"PFE":0.9},"content_text":"BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcastThe hosts are Reuters Breakingviews columnists. The opinions expressed are their own.By Aimee  Donnellan and Jonathan  Guilford\nDUBLIN/NEW YORK, Oct 16 (Reuters Breakingviews) - Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.\nListen to the podcast\nIn many cases, the market charges nearly triple what others do, a discrepancy that has put President Trump on the warpath. In this Viewsroom podcast, Breakingviews columnists discuss how Americans subsidize novel treatments and how tricky it will be to spread the burden.Follow Aimee Donnellan on LinkedIn.Follow Jonathan Guilford on X and LinkedIn.FURTHER READING\nBig Pharma prevails in art of the drug deal\n\nBig Pharma’s tariff win leaves lingering aches\n\nObesity kings’ buffet is slimmer than it looks\nVisit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.   (Editing by Sheryl Peña and Gregory Garner; Production by Aditya Srivastav)((katrina.hamlin@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}